(Q84936139)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Ashwin N Ananthakrishnan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Joshua R Korzenik

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

11 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

Digestive Diseases and Sciences

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

472-480

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21909990%20AND%20SRC:MED&resulttype=core&format=json

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

12 February 2020

cites work

1 reference

12 December 2020

Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease

1 reference

12 December 2020

Review article: the role of non-biological drugs in refractory inflammatory bowel disease

1 reference

12 December 2020

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

1 reference

12 December 2020

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

12 December 2020

The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

1 reference

12 December 2020

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

12 December 2020

Durability of infliximab in Crohn's disease: a single-center experience

1 reference

12 December 2020

Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.

1 reference

12 December 2020

Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis

1 reference

12 December 2020

Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study

1 reference

12 December 2020

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

12 December 2020

Health economic evaluations: the special case of end-stage renal disease treatment

1 reference

12 December 2020

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort

1 reference

12 December 2020

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

12 December 2020

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

12 December 2020

A claims-based Markov model for Crohn's disease

1 reference

12 December 2020

Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

12 December 2020

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

12 December 2020

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

12 December 2020

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

1 reference

12 December 2020

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

1 reference

12 December 2020

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

1 reference

12 December 2020

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

12 December 2020